Bio-Rad Laboratories Inc BIO.B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIO.B is a good fit for your portfolio.
News
-
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
-
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
-
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
-
Bio-Rad's stock leads the S&P 500 decliners, as they suffer the biggest selloff in 36 years after disappointing results.
Trading Information
- Previous Close Price
- $280.90
- Day Range
- $279.65–279.65
- 52-Week Range
- $269.05–417.25
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $7.98 Bil
- Volume/Avg
- 4 / 300
Key Statistics
- Price/Earnings (Normalized)
- 23.36
- Price/Sales
- 3.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 5.16%
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 8,030
- Website
- https://www.bio-rad.com
Competitors
Valuation
|
Metric
|
BIO.B
|
TMO
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.36 | 27.32 | 32.09 |
Price/Book Value | 0.88 | 4.95 | 3.59 |
Price/Sales | 3.11 | 5.38 | 8.59 |
Price/Cash Flow | 11.82 | 26.35 | 29.24 |
Price/Earnings
BIO.B
TMO
DHR
Financial Strength
|
Metric
|
BIO.B
|
TMO
|
DHR
|
|---|---|---|---|
Quick Ratio | 4.01 | 1.19 | 1.34 |
Current Ratio | 5.83 | 1.70 | 1.85 |
Interest Coverage | −18.24 | 4.83 | 15.85 |
Quick Ratio
BIO.B
TMO
DHR
Profitability
|
Metric
|
BIO.B
|
TMO
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 2.49% | 8.69% | 5.15% |
Return on Equity (Normalized) | 3.50% | 18.71% | 8.40% |
Return on Invested Capital (Normalized) | 2.78% | 10.97% | 6.02% |
Return on Assets
BIO.B
TMO
DHR
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Rqpmlxsj | Xqfwcj | $182.3 Bil | |
SYK
| Stryker Corp | Tvmkgtlypw | Mbxf | $123.5 Bil | |
MDT
| Medtronic PLC | Nrjlnbm | Lgyvpm | $111.9 Bil | |
BSX
| Boston Scientific Corp | Wtyzzzmgm | Qtlpprg | $108.0 Bil | |
EW
| Edwards Lifesciences Corp | Dsptdbcds | Sbqpqs | $52.1 Bil | |
DXCM
| DexCom Inc | Gthqpxtws | Clwzj | $49.5 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Qzjbttylkr | Kymzq | $24.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Pybnywmpy | Qhbnlx | $24.5 Bil | |
ALGN
| Align Technology Inc | Rxyzvbwdn | Mbdjmc | $20.5 Bil | |
PODD
| Insulet Corp | Hynsvjyjz | Tbhlf | $11.3 Bil |